Edition:
United Kingdom

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.27USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
41,851
52-wk High
$3.26
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Mei Pharma enters into at-market equity offering sales agreement
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Mei Pharma Inc :On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​.Pursuant to sales agreement co may sell, from time to time, an aggregate of up to $30 million of common stock - SEC filing.  Full Article

MEI pharma reports fiscal year 2016 results
Tuesday, 6 Sep 2016 

MEI Pharma Inc :MEI Pharma reports fiscal year 2016 results.  Full Article

Helsinn Investment Fund reports 7.1 pct passive stake in MEI Pharma - SEC filing
Monday, 22 Aug 2016 

Helsinn Investment Fund SA:Helsinn Investment Fund SA reports 7.1 pct passive stake in MEI Pharma Inc as of Aug. 16 - SEC filing.  Full Article

Helsinn Group, MEI Pharma enter deal for Pracinostat development
Monday, 8 Aug 2016 

MEI Pharma Inc : Helsinn Group and Mei Pharma enter strategic agreement for the development and commercialization of pracinostat for the treatment of acute myeloid leukemia and other hematologic diseases . To receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales . Helsinn, co to collaborate to explore optimal dosing regimen of pracinostat in combination with azacitidine for treatment of high-risk mds .Agreement enables Helsinn to expand into oncology therapeutics with new phase iii-ready asset.  Full Article

MEI pharma's pracinostat receives FDA's breakthrough therapy designation
Monday, 1 Aug 2016 

MEI Pharma Inc : MEI Pharma's pracinostat receives breakthrough therapy designation from FDA for treatment in combination with azacitidine of patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy .Agreement has been reached with FDA on company's proposed phase III study design.  Full Article

BRIEF-Mei Pharma enters into at-market equity offering sales agreement

* On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​